Pacific Biosciences Of California (PACB) financials
Pacific Biosciences Of California revenue and earnings by year
Pacific Biosciences Of California's revenue was $160 million in the fiscal year to December 31, 2025, up 3.9% from the year before. Net income was -$546 million, -341.5% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 6.5% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 160 | 154 | 201 | 128 | 131 | 79 | 91 | 79 | 93 | 91 |
| Revenue growth | 3.9% | -23.2% | 56.3% | -1.7% | 65.4% | -13.2% | 15.6% | -15.9% | 3.0% | — |
| Gross profit | 46 | 37 | 53 | 49 | 59 | 33 | 35 | 25 | 35 | 44 |
| Gross margin | 28.6% | 24.2% | 26.3% | 38.2% | 45.1% | 41.3% | 38.0% | 31.9% | 37.1% | 48.7% |
| Operating income | -573 | -475 | -319 | -305 | -209 | -104 | -101 | -101 | -90 | -71 |
| Operating margin | -357.8% | -308.5% | -159.3% | -237.6% | -160.4% | -132.3% | -110.6% | -128.4% | -96.1% | -78.5% |
| Net income | -546 | -310 | -307 | -314 | -181 | 29 | -84 | -103 | -92 | -74 |
| Net margin | -341.5% | -201.2% | -153.0% | -244.9% | -138.9% | 37.3% | -92.6% | -130.4% | -98.6% | -82.0% |
| Diluted EPS | -$1.82 | — | -$1.21 | -$1.40 | -$0.89 | $0.17 | -$0.55 | -$0.77 | -$0.88 | -$0.83 |
| Free cash flow | -114 | -212 | -268 | -280 | -117 | 18 | -81 | -68 | -78 | -76 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open PACB in Markets.
How Pacific Biosciences Of California makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Consumable | $20.1M | 51.6% |
| Instrument | $12.8M | 32.9% |
| Service & Other | $6.06M | 15.5% |
See also: PACB returns
No forecast, no recommendation. This page describes Pacific Biosciences Of California from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.